Menu

Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients


Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related:

Recent Campus Connections News:

The Best Dive Bar In Every State (North Carolina) - He’s Not Here

Cooler on the Other Side: The Extraordinary Life and Legacy of Stuart Scott

New decade, same Sutton's: Patrons reminisce on legacy of a Tar Heel classic

Two UNC alumnae named recipients of Marshall Scholarship

Mipso - The Unlikely Story Of A Band With A Lot To Like


© 2005-2020 Tar Heel Times | Contact | Privacy Policy | Site Map | RSS | Did UNC Win?

Tar Heel Times is an unofficial resource for UNC fans and is not affiliated with the University of North Carolina.